Foundational guide
FOXO4-DRI Protocol: Experimental Design, Not Clinical
Two documents share the name. One specifies how an experiment was run in mice and exists in the literature; the other specifies how a compound is given to people and has never been written.
A FOXO4-DRI protocol exists in one sense and not in the other, and the ambiguity accounts for most of the confusion around this search.
Experimental protocols for this compound are public and detailed. A clinical protocol has never been written, because no human trial has ever been designed.
Supplier publishing lot-level data
FOXO4-DRI, Ascension Peptides
Two independent laboratories have certified this product, though on different batches. The code below halves the listed price on the vial.
The two published certificates cover different lots and disagree on fill: Kovera Labs assays batch 55-05260628 at 11.41 mg, MZ Biolabs assays lot 55-01260229 at 8.30 mg, both against a 10 mg label, moving the real figure between $5.87/mg and $8.07/mg. Endotoxin and sterility screens appear on the Kovera lot only, so testing scope here is a batch property rather than a product feature. The vendor spells the product FOX04 with a zero, including in the link.
- Kovera Labs and MZ Biolabs certificates, different lots
- Carriage free above $250
- Same-day dispatch before 2pm CST
Laboratory research material only, not for human consumption. FOXO4-DRI holds no marketing authorisation in any market and has never been administered in a registered human trial. Affiliate links: we may earn a commission at no additional cost to you. Figures checked September 2, 2026.
The distinction the search term hides
A clinical protocol specifies eligibility criteria, dose, route, schedule, primary and secondary endpoints, safety monitoring, stopping rules and statistical analysis. It is reviewed by an ethics committee and registered before enrolment. None exists for FOXO4-DRI anywhere.
An experimental protocol is the methods section of a laboratory study: model system, compound, concentration or dose, schedule, and the assays used to determine whether anything happened. Several exist and are published.
Material circulating as a protocol PDF for this compound is neither. It is typically assembled by a third party from the animal literature and presented with a confidence the underlying evidence does not carry.
What the published protocols specify
The 2017 study ran several distinct arms, which is part of why its conclusions were taken seriously.
Later work applied the compound in its own systems with its own parameters: aged mouse Leydig cells and testosterone secretion, spermatogenesis in aged mice, keloid fibroblasts, bleomycin-induced pulmonary fibrosis in mice, and human chondrocytes expanded in culture. The chondrocyte study is frequently miscited as human evidence; it is human cells in a dish, which is a different category of claim.
| Arm | Model | Dosing | Primary readout |
|---|---|---|---|
| Chemotoxicity | Mice given doxorubicin 10 mg/kg | 5 mg/kg, days 1, 3, 5, intravenous | Reduction in chemotherapy damage |
| Fast ageing | XpdTTD/TTD mice, DNA-repair defect | Intraperitoneal | Fitness, fur density, renal function |
| Natural ageing | Naturally aged mice | Intraperitoneal | Fitness, fur density, renal function |
| In vitro | Doxorubicin-senescent cells | Varied by experiment | Viability against other senolytics |
The readouts, which are the substance of a protocol
Protocols are commonly reduced to their dosing, but in senescence research the assay is at least as important, because the effect is not directly observable.
The standard markers are senescence-associated beta-galactosidase activity, which stains senescent cells; p16 and p21, cell-cycle inhibitors that rise as cells enter senescence; and the inflammatory secretory profile those cells produce. The 2017 work additionally used a p16-driven bioluminescent reporter, allowing senescent-cell burden to be imaged longitudinally in a living animal rather than inferred from terminal tissue sampling.
None of these is available outside a laboratory. That is a decisive practical point: a self-directed protocol would be uninterpretable in principle, because there would be no way to determine whether the intervention had done anything at all.
Why the schedule was intermittent
Three administrations across five days reflects a mechanistic rationale rather than a tolerability limit.
A senolytic eliminates a cell population. Once cleared, there is nothing further for the compound to act upon until senescent cells re-accumulate, which occurs over months to years. Continued exposure adds risk without corresponding benefit, and since selectivity is comparative rather than absolute, prolonged exposure widens the window for off-target apoptosis.
The binding mechanism was characterised structurally in 2025, identifying the disordered transactivation domain of p53 as the target of both FOXO4 and FOXO4-DRI. Mechanistic resolution of that quality is sometimes read as clinical maturity. It is not; no trial has followed in the nine years since the founding paper.
Frequently asked questions
- Is there a clinical FOXO4-DRI protocol?
- No. No human trial has been designed or registered, so no clinical protocol exists. Documents circulating as such are compiled by third parties from animal literature.
- What did the published experimental protocols use?
- 5 mg/kg in mice, three administrations on alternating days, intravenous in the chemotoxicity arm and intraperitoneal in the ageing arms, with senescence markers and a p16 reporter as readouts.
- Why was dosing intermittent?
- Because a senolytic clears a cell population rather than sustaining a signal. After clearance there is nothing to act on until cells re-accumulate, so continued exposure adds risk without benefit.
- Could I follow an experimental protocol myself?
- The readouts make it pointless. Senescence-associated beta-galactosidase staining, p16 and p21 quantification and bioluminescent reporters require laboratory instrumentation, so there would be no way to tell whether anything happened.
Limitations of the evidence
This guide describes published experimental protocols in animal and in-vitro models. It does not provide a protocol for human use and none exists. The readouts described require laboratory instrumentation and are not observable outside that setting.
References
Citations are annotated with an evidence tier reflecting study design and replication. See Methodology for criteria.
- 1.Baar MP, Brandt RMC, Putavet DA, et al. · Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell · 2017PMID 28340339Preclinical
- 2.Bourgeois B, Spreitzer E, Platero-Rochart D, et al. · The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI · Nature Communications · 2025PMID 40593617Preclinical
- 3.Frontiers in Bioengineering and Biotechnology · Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes · Frontiers in Bioengineering and Biotechnology · 2021PMID 33996787Preclinical